The Autism Biomarkers Consortium for Clinical Trials: Clinical Characteristics and Interim Evaluation of Clinical Measures Commonly Used in Clinical Trials
S. Faja1, R. A. Bernier2, G. Dawson3, K. Chawarska4, S. Jeste5, C. A. Nelson6, S. J. Webb7, F. Shic8, A. Naples9, C. Sugar10, M. Murias11, J. Dziura12, C. Brandt13 and J. C. McPartland9, (1)Division of Developmental Medicine, Boston Children's Hospital / Harvard Medical School, Brookline, MA, (2)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (3)Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, (4)Child Study Center, Yale University School of Medicine, New Haven, CT, (5)Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, (6)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA, (7)Center, Seattle Children’s Research Institute & University of Washington, Seattle, WA, (8)Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, (9)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (10)Department of Biostatistics, UCLA, Los Angeles, CA, (11)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (12)Emergency Medicine, Yale School of Medicine, New Haven, CT, (13)Yale University, New Haven, CT